Patents by Inventor Shaomeng Wang

Shaomeng Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STAT3 PROTEIN DEGRADERS
    Publication number: 20260347381
    Abstract: The present disclosure provides compounds represented by Formulae I and IV: wherein R1a, R1b, R2a, R2b, A, E, QD, and QE are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are degraders of STAT3. Compounds of Formula IV are inhibitors of STAT3. STAT3 degraders and inhibitors are useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: March 9, 2026
    Publication date: November 5, 2026
    Inventors: Shaomeng Wang, Haibin Zhou, Renqi Xu
  • Cereblon Ligands and Uses Thereof
    Publication number: 20260317298
    Abstract: Described herein are compounds and conjugates of Formulae I and II and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as cereblon-binding agents and bifunctional degraders for certain proteins).
    Type: Application
    Filed: July 11, 2023
    Publication date: October 15, 2026
    Inventors: Guozhang Xu, Zhenwu Li, Shaomeng Wang, Xuqing Zhang
  • Cereblon Ligands and Uses Thereof
    Publication number: 20260265271
    Abstract: Described herein are compounds or conjugates of Formulae II and I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).
    Type: Application
    Filed: July 11, 2023
    Publication date: September 10, 2026
    Inventors: Shaomeng Wang, Rohan Rej, Zhixiang Chen, Longchuan Bai, Ranjan Kumar Acharyya, Dimin Wu, Paul Kirchhoff, Guozhang Xu, Zhenwu Li
  • Small molecule degraders of STAT3
    Patent number: 12729213
    Abstract: The present disclosure provides compounds represented by Formula I or Formula VIII: wherein R1a, R1b, M, A, E, QA, and QB are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are degraders of STAT3 or degraders of STAT3 and STAT1. Compounds of Formula VIII are inhibitors of STAT3. STAT3 degraders and inhibitors are useful for the treatment of cancer and other diseases.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: September 8, 2026
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Haibin Zhou, Renqi Xu, Longchuan Bai, Donna McEachern, Jeanne Stuckey, Chao-Yie Yang
  • INDAZOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20260256925
    Abstract: Described herein are compounds of Formula I and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).
    Type: Application
    Filed: July 12, 2023
    Publication date: September 3, 2026
    Inventors: Zhixiang Chen, Rohan Rej, Guozhang Xu, Dimin Wu, Ranjan Kumar Acharyya, Mingliang Wang, Biao Hu, Jianfeng Lu, Shaomeng Wang
  • COMPOUNDS AND COMPOSITIONS AS STAT3 DEGRADERS AND USES THEREOF
    Publication number: 20260226086
    Abstract: Described herein are compounds of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., for degrading certain proteins such as STAT3).
    Type: Application
    Filed: February 13, 2024
    Publication date: August 6, 2026
    Inventors: Shaomeng Wang, Ranjan Kumar Acharyya, Longchuan Bai, Haibin Zhou, Dimin Wu, Donna McEachern
  • MDM2 protein degraders
    Patent number: 12637473
    Abstract: The present disclosure provides compounds represented by Formula I-A: A1-L1-B1??I-A and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein A1, B1, and L1 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a condition or disorder responsive to degradation of MDM2 protein such as cancer.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: May 26, 2026
    Assignee: REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Yangbing Li, Jiuling Yang, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Rohan Rej, Xin Han
  • Compounds and Compositions as VHL Ligands and STAT3 Degraders Uses Thereof
    Publication number: 20260108613
    Abstract: Described herein are compounds or conjugates of Formula I or II and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as VHL-binding agents or bifunctional degraders for degrading certain proteins (e.g., STAT3)).
    Type: Application
    Filed: December 19, 2025
    Publication date: April 23, 2026
    Inventors: Shaomeng Wang, Haibin Zhou, Dimin Wu, Ranjan Kumar Acharyya, Longchuan Bai, Donna McEachern, Hoda Metwally, Mi Wang, Paul Kirchhoff, Jelena Tosovic
  • COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF
    Publication number: 20260092071
    Abstract: Described herein are compounds of Formula II and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as SMARCA2 or SMARCA4 degraders).
    Type: Application
    Filed: September 22, 2023
    Publication date: April 2, 2026
    Inventors: Shaomeng Wang, Lingying Leng, Lin Yang, Wenbin Tu, Liyue Huang, Mi Wang, Wei Jiang, Paul Kirchhoff, Guozhang Xu, Zhenwu Li, Lalgudi Harikrishnan, E. Scott Priestley, Jelena Tosovic, Jeanne Stuckey
  • STAT3 protein degraders
    Patent number: 12570679
    Abstract: The present disclosure provides compounds represented by Formulae I and IV: wherein R1a, R1b, R2a, R2b, A, E, QD, and QE are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are degraders of STAT3. Compounds of Formula IV are inhibitors of STAT3. STAT3 degraders and inhibitors are useful for the treatment of cancer and other diseases.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: March 10, 2026
    Assignee: REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Haibin Zhou, Renqi Xu
  • TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20260028354
    Abstract: Described herein are compounds of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as estrogen receptor degraders).
    Type: Application
    Filed: July 12, 2023
    Publication date: January 29, 2026
    Inventors: Guozhang Xu, Zhixiang Chen, Rohan Rej, Ranjan Kumar Acharyya, Dimin Wu, Ms. Mingliang Wang, Biao Hu, Jianfeng Lu, Zhenwu Li, E. Scott Priestley, Shaomeng Wang
  • Small molecule STAT protein degraders
    Patent number: 12522623
    Abstract: The present disclosure provides compounds represented by Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R3a, R4, A, E1, E2, M, and Q are as set forth in the specification. Compounds of Formula (I) are STAT protein degraders and thus are useful for the treatment of cancer and other diseases.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: January 13, 2026
    Assignee: REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Haibin Zhou, Renqi Xu, Longchuan Bai, Donna McEachern, Jeanne Stuckey, Chao-Yie Yang
  • INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20260007681
    Abstract: Described herein are compounds of Formula I and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).
    Type: Application
    Filed: July 12, 2023
    Publication date: January 8, 2026
    Inventors: Rohan Rej, Zhixiang Chen, Mingliang Wang, Dimin Wu, Guozhang Xu, Ranjan Kumar Acharyya, Biao Hu, Jianfeng Lu, Shaomeng Wang
  • CHROMAN DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20260000676
    Abstract: Described herein are compounds of Formula (I) and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).
    Type: Application
    Filed: July 12, 2023
    Publication date: January 1, 2026
    Inventors: Guozhang Xu, Ranjan Kumar Acharyya, Rohan Rej, Zhixiang Chen, Biao Hu, Jianfeng Lu, Shaomeng Wang
  • IKZF2 DEGRADERS AND USES THEREOF
    Publication number: 20250215012
    Abstract: Described herein are compounds of Formulae I? and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as IKZF2 degraders).
    Type: Application
    Filed: March 24, 2023
    Publication date: July 3, 2025
    Inventors: Zhixiang Chen, Rohan Rej, Xuqing Zhang, Longchuan Bai, Paul Kirchhoff, Shaomeng Wang
  • CEREBLON LIGANDS AND USES THEREOF
    Publication number: 20250195484
    Abstract: Described herein are compounds or conjugates of Formula II and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).
    Type: Application
    Filed: March 24, 2023
    Publication date: June 19, 2025
    Inventors: Haibin Zhou, Dimin Wu, Changwei Wang, Mi Wang, Shaomeng Wang, Rohan Rej, Zhixiang Chen, Ranjan Kumar Acharyya, Longchuan Bai, Paul Kirchhoff, Guozhang Xu, Xuqing Zhang, Zhenwu Li, Biao Hu, Jianfeng Lu
  • Macrocyclic fused pyrazoles as Mcl-1 inhibitors
    Patent number: 12319703
    Abstract: Provided are compounds represented by Formula IA: (IA), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, L1, L2, L3, X, A, B and C are as defined as set forth in the specification. Also provided compounds of Formula IA for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: June 3, 2025
    Assignees: ASCENTAGE PHARMA (SUZHOU) CO., LTD., REGENTS OF THE UNIVERSITY OF MICHIGAN, ASCENTAGE PHARMA GROUP CORP LIMITED
    Inventors: Guozhi Tang, Dongbo Li, Liugen Li, Xianchan Zha, Wenming Chen, Shaomeng Wang, Chao-Yie Yang
  • IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF
    Publication number: 20250034162
    Abstract: The present disclosure provides compounds represented by Formula I: wherein R1, R2, R3, and R4 are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are EED inhibitors. EED inhibitors are useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: September 17, 2024
    Publication date: January 30, 2025
    Inventors: Shaomeng Wang, Rohan Rej, Changwei Wang, Mi Wang, Jianfeng Lu, Chao-Yie Yang, Ester Fernandez-Salas, Jeanne Stuckey
  • Imidazopyrimidines as EED inhibitors and the use thereof
    Patent number: 12145944
    Abstract: The present disclosure provides compounds represented by Formula I: wherein R1, R2, R3, and R4 are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are EED inhibitors. EED inhibitors are useful for the treatment of cancer and other diseases.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: November 19, 2024
    Assignee: REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Rohan Rej, Changwei Wang, Mi Wang, Jianfeng Lu, Chao-Yie Yang, Ester Fernandez-Salas, Jeanne Stuckey
  • Small molecule DCN1 inhibitors and therapeutic methods using the same
    Patent number: 12012467
    Abstract: Compounds of formula (I) as inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: June 18, 2024
    Assignee: REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Haibin Zhou, Jianfeng Lu, Liu Liu, Yi Sun, Denzil Bernard